Blood-brain barrier permeability and cerebral perfusion in Alzheimer*s disease

Recruiting

• Conditions: neurodegeneratieve aandoeningen; Alzheimer's disease; dementia

• Registration Number: NL-OMON38302
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Patients with AD:
• Informed consent before participation in the study
• Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
• Diagnosed with dementia of the Alzheimer*s type
• Clinical dementia rating (CDR) of 1, which means a mild to moderate stage of dementia
• MMSE >= 20 and patients are mentally competent This inclusion criterion is conform the Parelsnoer Initiative inclusion criteria. By the Parelsnoer Initiative, individuals with an MMSE >=18 are considered mentally competent.;Patients with prodromal AD:
• Informed consent before participation in the study
• Received standard diagnostic procedure according to the Parelsnoer Initiative procedure
• Diagnosis of prodromal dementia according to the Dubois criteria (16)
• CDR of 0.5, which suggests a very mild stage of dementia
• Memory impairment defined as Delayed Recall on Verbal Learning Test (15 WLT) <1.5 SD
• MMSE >= 20 and patients are mentally competent.
• Medial temporal lobe atrophy scale MTA >= 1 (17) OR abnormal levels of Aß42, t-tau or p-tau;Healthy participants:
• Informed consent before participation in the study
• No Diagnosis of dementia, prodromal dementia, or mild cognitive impairment.
• MMSE >= 26
• No substantial memory complaints (according to participant ánd partner/relative)
• Age, gender and education is matched to the patient groups.

Exclusion Criteria

• Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos)
• Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR < 30 mL/min.
• Major vascular disorders (e.g. stroke, heart disease)
• Psychiatric or neurological disorders (e.g. Major depression; history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder; cognive impairment due to alcohol abuse; epilepsy, Parkinson*s disease, MS, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Meniere*s disease, brain infections)
• Structural abnormalities of the brain
• Cognitive impairment due to alcohol/drug abuse
• Absence of reliable informant (for AD patient groups)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study measures are blood brain barrier permeability as measured by<br /><br>T1-weighted dynamic contrast MRI; and cerebral perfusion as measured by<br /><br>Arterial Spin Labeling MRI. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>